In clinical trials, individuals receiving Semaglutide achieved weight loss of up to 15% of total body weight over 68 weeks when combined with lifestyle interventions2,3
At the moment, the use of such drugs is almost exclusively limited to people with a clear medical need to lose weight
Parallel fibrogenesis in the liver and myocardium adds to ventricular stiffness and diastolic dysfunction, while gut dysbiosis from a Western diet heightens systemic inflammation and endotoxemia, worsening cardiac and hepatic dysfunction
In an unprecedented move, the Trump administration issued an Addendum to the OPM Call Letter on January 31, 2025 stating that OPM no longer require[s] Plan Year 2026 proposals to clarify or update the obesity management benefit to include the elements listed in the bullets starting on the bottom of page 10 and continuing through the bottom of page 12 of Carrier Letter 2025-01. In other words, the evidence-based policy guidance to better manage the obesity benefit issued two weeks earlier no longer required carriers attention
This is not academic trivia
